GENPREX INC (GNPX)

Q: What's priced into GENPREX INC (GNPX) stock?

The evidence snapshot provides no valuation measure or clear account of market expectations, so whether GNPX is cheap or expensive versus peers cannot be assessed. The recent share-price reaction is described as down, but that alone does not show what expectations are priced in.

Q: What does the GENPREX INC (GNPX) outlook hinge on?

The multi-year thesis hinges on whether Reqorsa clinical development can advance toward commercial progress while the company manages its losses and cash needs. Near-term sector support could strengthen if Healthcare bellwethers continue to report well, while weaker jobs data or bellwether results could weaken that backdrop. The evidence for a favorable company-specific catalyst is thin.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.81-8.59%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge GENPREX INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-5,720
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-1,265
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-10,560

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce negative cash from operations to about -$3.14M per quarter	Cash burn has improved from negative $5.8M to negative $3.14M per quarter.	Broken	cash burn worsens below -$4M per quarter next year	Cash from operations: $-5.139M FY2026-Q2; GAAP. Published target: cash from operations >= -$3.14M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 14, 2026-5,138,699 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$4.68M in 2025-Q2 to -$4.48M in 2026-Q2, while cash from operations worsened from -$2.19M in 2024-Q3 to -$5.14M in 2026-Q2. Management continues to manage losses but financials show persistent negative cash flow and operating losses, indicating limited progress on reducing burn. Delivery assessment Oct 24, 2026
Advance clinical development of Reqorsa Gene Therapy	Genprex is advancing clinical research on its cancer gene therapy.	Under Pressure	progress score falls below 30% next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. While no revenue is reported, management has consistently emphasized advancing clinical development through collaborations and patent expansions. The trajectory shows persistent focus with positive research milestones but no commercial revenue yet. Delivery assessment Oct 24, 2026
Protect and expand IP portfolio for gene therapy products	Genprex is advancing clinical research on its cancer gene therapy.	Intact	loss of key patents or IP rights	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 4 quarters. Management has secured multiple patents expanding the intellectual property portfolio for Reqorsa Gene Therapy. While no direct financial impact is reported, the company is actively protecting and expanding IP rights, showing consistent delivery on this priority. Delivery assessment Oct 24, 2026
Manage operating losses near $4.46M per quarter	The company is working to control losses around $4.46M per quarter.	Broken	net loss exceeds $5M per quarter next year	Net income: $-4.447M FY2026-Q2; GAAP. Published target: net loss <= $4.46M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 14, 2026-4,447,219 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 292ab696-d58d-4b97-b668-86e131a210ff. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$4.68M in 2025-Q2 to -$4.48M in 2026-Q2, while cash from operations worsened from -$2.19M in 2024-Q3 to -$5.14M in 2026-Q2. Management continues to manage losses but financials show persistent negative cash flow and operating losses, indicating limited progress on reducing burn. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 0
2026-07-25	Unavailable	Unavailable	1 / 0
2026-07-26	Unavailable	Unavailable	1 / 0
2026-07-27	Unavailable	Unavailable	1 / 0
2026-07-28	Unavailable	Unavailable	1 / 0
2026-07-29	Unavailable	Unavailable	1 / 0
2026-07-30	Unavailable	Unavailable	1 / 0
2026-07-31	Unavailable	Unavailable	1 / 0
2026-08-01	Unavailable	Unavailable	1 / 0
2026-08-02	Unavailable	Unavailable	1 / 0
2026-08-03	Unavailable	Unavailable	1 / 0
2026-08-04	Unavailable	Unavailable	1 / 0
2026-08-05	Unavailable	Unavailable	1 / 0
2026-08-06	Unavailable	Unavailable	1 / 0
2026-08-07	Unavailable	Unavailable	1 / 0
2026-08-08	Unavailable	Unavailable	1 / 0
2026-08-09	Unavailable	Unavailable	1 / 0
2026-08-10	Unavailable	Unavailable	1 / 0
2026-08-12	Unavailable	Unavailable	1 / 0
2026-08-13	Unavailable	Unavailable	1 / 0
2026-08-14	Unavailable	Unavailable	1 / 0
2026-08-15	Unavailable	Unavailable	1 / 0
2026-08-16	Unavailable	Unavailable	1 / 0
2026-08-17	Unavailable	Unavailable	1 / 0
2026-08-18	Unavailable	Unavailable	1 / 0
2026-08-19	Unavailable	Unavailable	1 / 0
2026-08-20	Unavailable	Unavailable	1 / 0
2026-08-21	Unavailable	Unavailable	1 / 0
2026-08-22	Unavailable	Unavailable	1 / 0
2026-08-23	Unavailable	Unavailable	1 / 0
2026-08-24	Unavailable	Unavailable	1 / 0
2026-08-25	Unavailable	Unavailable	1 / 0
2026-08-26	Unavailable	Unavailable	1 / 0
2026-08-27	Unavailable	Unavailable	1 / 0
2026-08-28	Unavailable	Unavailable	1 / 0
2026-08-29	Unavailable	Unavailable	1 / 0
2026-08-30	Unavailable	Unavailable	1 / 0
2026-08-31	Unavailable	Unavailable	1 / 0
2026-09-01	Unavailable	Unavailable	1 / 0
2026-09-02	Unavailable	Unavailable	1 / 0
2026-09-03	Unavailable	Unavailable	1 / 0
2026-09-04	Unavailable	Unavailable	1 / 0
2026-09-05	Unavailable	Unavailable	1 / 0
2026-09-06	Unavailable	Unavailable	1 / 0
2026-09-07	Unavailable	Unavailable	1 / 0
2026-09-08	Unavailable	Unavailable	1 / 0
2026-09-09	Unavailable	Unavailable	1 / 0
2026-09-10	Unavailable	Unavailable	1 / 0
2026-09-11	Unavailable	Unavailable	1 / 0
2026-09-12	Unavailable	Unavailable	1 / 0
2026-09-13	Unavailable	Unavailable	1 / 0
2026-09-14	Unavailable	Unavailable	1 / 0
2026-09-15	Unavailable	Unavailable	1 / 0
2026-09-16	Unavailable	Unavailable	1 / 0
2026-09-17	Unavailable	Unavailable	1 / 0
2026-09-18	Unavailable	Unavailable	1 / 0
2026-09-19	Unavailable	Unavailable	1 / 0
2026-09-20	Unavailable	Unavailable	1 / 0
2026-09-21	Unavailable	Unavailable	1 / 0
2026-09-22	Unavailable	Unavailable	1 / 0
2026-09-23	Unavailable	Unavailable	1 / 0
2026-09-24	Unavailable	Unavailable	1 / 0
2026-09-25	Unavailable	Unavailable	1 / 0
2026-09-26	Unavailable	Unavailable	1 / 0
2026-09-27	Unavailable	Unavailable	1 / 0
2026-09-28	Unavailable	Unavailable	1 / 0
2026-09-29	Unavailable	Unavailable	1 / 0
2026-09-30	Unavailable	Unavailable	1 / 0
2026-10-01	Unavailable	Unavailable	1 / 0
2026-10-02	Unavailable	Unavailable	1 / 0
2026-10-03	Unavailable	Unavailable	1 / 0
2026-10-04	Unavailable	Unavailable	1 / 0
2026-10-05	Unavailable	Unavailable	1 / 0
2026-10-06	Unavailable	Unavailable	1 / 0
2026-10-07	Unavailable	Unavailable	1 / 0
2026-10-08	Unavailable	Unavailable	1 / 0
2026-10-09	Unavailable	Unavailable	1 / 0
2026-10-10	Unavailable	Unavailable	1 / 0
2026-10-11	Unavailable	Unavailable	1 / 0
2026-10-12	Unavailable	Unavailable	1 / 0
2026-10-13	Unavailable	Unavailable	1 / 0
2026-10-14	Unavailable	Unavailable	1 / 0
2026-10-15	Unavailable	Unavailable	1 / 0
2026-10-16	Unavailable	Unavailable	1 / 0
2026-10-17	Unavailable	Unavailable	1 / 0
2026-10-18	Unavailable	Unavailable	1 / 0
2026-10-19	Unavailable	Unavailable	1 / 0
2026-10-20	Unavailable	Unavailable	1 / 0
2026-10-21	Unavailable	Unavailable	1 / 0
2026-10-22	Unavailable	Unavailable	1 / 0
2026-10-23	Unavailable	Unavailable	1 / 0
2026-10-24	Unavailable	Unavailable	1 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Monthly analyst history is unavailable.

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce negative cash from operations to about -$3.14M per quarterPublished status: Broken
Advance clinical development of Reqorsa Gene TherapyPublished status: Under Pressure
Protect and expand IP portfolio for gene therapy productsQualitative condition
Manage operating losses near $4.46M per quarterPublished status: Broken

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.5%Typical daily move · historical

Downside history

-99.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

GENPREX INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not a proven earnings compounder. The multi-year thesis is in a watch state: clinical progress and intellectual-property work continue, but management execution is volatile and the company remains loss-making.

What's priced into GENPREX INC

The evidence snapshot provides no valuation measure or clear account of market expectations, so whether GNPX is cheap or expensive versus peers cannot be assessed. The recent share-price reaction is described as down, but that alone does not show what expectations are priced in.

What the fundamentals likely do

Near-term results are likely to remain pressured by operating losses and worsening cash from operations; progress on reducing cash burn has been limited. Clinical development of Reqorsa remains the main stated priority, but there is no reported revenue, and the next-quarter earnings-miss risk is elevated. A recent litigation filing and an earlier listing-rule notice add near-term uncertainty.

What GENPREX INC hinges on